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Introduction 
Enterobacter sakazakii is a motile peritrichous, Gram-negative non-spore 
forming facultative anaerobic bacillus belonging to the family 
Enterobacteriaceae, genus Enterobacter.  The microbe was listed as a new 
species in 1980 [1].  Using DNA-DNA hybridisation and biochemical tests 
Farmer et al. defined the species and identified fifteen distinct biogroups[1] 
with a new biogroup being added recently[2].  Based on genotyping and 
biotyping E. sakazakii represents a genetically diverse and taxonomically ill-
defined species[2-5]. 
 
Enterobacter sakazakii is recognised as an emerging opportunistic pathogen 
and is the aetiological agent in rare cases of meningitis, necrotising 
enterocolitis and bacteremia in infants[6-15].  Since the first case of meningitis 
in an infant iwas described in England in 1958[16], neonatal infections 
involving E. sakazakii have been reported from all parts of the developing 
world with many of these resulting in the deaths of more than seventy infants 
Table 1. 
 
Sources of E. sakazakii illness have not been extensively investigated and 
therefore the origin of the bacterium remains unknown.  However, several 
reports have implicated contaminated powdered infant formula (PIF) as a 
source of E. sakazakii in neonatal infection[8, 14, 17, 18].  In 2004, several 
high profile recalls of PIF contaminated with E. sakazakii from Asia, South 
America and Europe (WHO/FAO, 2006) occurred. 
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These developments have focused attention on this pathogen, by both the 
PIF manufacturers and the health professionals.  A revision of the 
microbiological standards applied by PIF producers has taken place, with the 
implementation of updated testing requirements, underpinned by legislation, 
aimed at reducing the risk of dissemination of the pathogen through powdered 
products.  Attention has also focused on the development of guidelines for the 
correct preparation of PIF in hospitals and in homes. 
 
This review will describe the microbiology of E. sakazakii, provide an 
understanding of its epidemiology and examine its role in public health.  We 
will also aim to highlight the issues surrounding the proper reconstitution of 
PIF prior to the feeding of infants. 
 
Taxonomy and background of Enterobacter sakazakii 
Enterobacter sakazakii was originally referred to as a “yellow-pigmented” 
Enterobacter cloacae.  It was subsequently re-defined as a new bacterial 
species in 1980[1].  Farmer et al.,[1] originally described 15 biogroups 
including 57 strains, based on biochemical profiles with five strains used to 
define the species by DNA-DNA hybridisations.  These data suggested that 
the biogroups may represent more than one species and that E. sakazakii 
was 41-54% related to Enterobacter and Citrobacter species.  Detailed 
phylogenetic analysis of 16S rDNA and hsp60 genes confirmed the diverse 
heterogeneity that existed between strains and further analysis of these gene 
sequences showed the presence of four distinct genetic clusters, all of which 
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contained strains of clinical origin[3-5].  In a recent extension of the initial 
study [1], Iversen et al.,[2] analysed 189 strains using geno- and phenotypic 
methods and showed that a new biogroup (known as biogroup 16) could be 
defined.  Further analysis determined that biogroup 1 included 32% of all 
known strains, whilst genogroup 1 was the largest and most genetically 
diverse cluster containing 90% of the studied strains and representing 
biogroups 1-5, 7-9, 11, 13 and 14. 
 
No evidence has been presented to suggest that there may be differences in 
the virulence capacity of any one genomo- or biogroup.  Therefore for the 
purposes of diagnosis, all 16 biogroups should be considered as potential 
threats to infant health.  
 
Infection and epidemiology 
Infections resulting from E. sakazakii are rare.  Nevertheless, they are a 
serious cause of fatal meningitis, necrotising enterocolitis and bacteremia in 
infants.  Interestingly, although E. sakazakii infections (including osteomyelitis 
and bacteremia) have been reported in immunocomprimised elderly 
patents[19, 20], infants appear to be the group at particular risk with neonates, 
especially those born prematurely or of low birth weight (< 2,500 g) reported 
to be in the highest risk category[20, 21].  In a recent risk analysis of 46 
clinical cases two groups were identified, 
(a) those infants born close to gestation age and of normal birth weight, 
and who developed meningitis in the neonatal period and 
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(b) premature infants, who developed bacteremia after one month of 
age[22].  The differences in the apparent timing of disease onset was likely 
due to the infant feeding practices wherein, premature infants are normally fed 
using sterile formula only, whilst full term babies consume prepared PIF.  
However, this may be an over simplification, since, immuno-compromised 
infants up to 10 months have developed blood stream infections and formerly 
healthy infants have developed meningitis after the neonatal period.  
Furthermore asymptomatic infants have demonstrated stool carriage for up to 
18 weeks[9].  Based on current estimates, one in 100,000 births may be 
infected with E. sakazakii. 
 
The clinical outcomes of infants with meningitis compared those with 
bacteremia differs as the later generally result in a better prognosis (mortality 
rate of 10%)[22].  Conversely, those with meningitis often develop clinical 
complications including ventriculitis, seizures, brain abscess, cerebral 
infarction and cyst formation.  Mortality rates of up to 80% have been 
reported[20] and these infections often associated with significant morbidity.  
Ninety-four % of meningitis survivors can develop neurological sequalae, 
including hydrocephalus, quadriplegia, impaired sight and hearing, and 
retarded neural development.  Early intervention is critical, and computed 
tomography or magnetic resonance imaging is recommended to identify 
cerebral abnormalities in suspected cases of meningitis.  
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Origin and transmission of E. sakazakii 
Enterobacter sakazakii is a ubiquitous organism found in a variety of foods.  It 
has been cultured from a range of foods including; dried baby food, milk 
powder, cheese, sausage meet, vegetables, dry food ingredients, rice, lettuce, 
sour tea, bread and herbs and spices and PIF[21, 23, 24].  The bacterium has 
also been isolated from both environmental and clinical sources.  
Documented environmental sources include house holds, food factories and 
PIF manufacturing facilities[23, 25]Mullane in submission].  Microbiological 
analysis of surface water, rotting wood, soil, grain, bird droppings, domestic 
animals, livestock and cows milk failed to yield a positive E. sakazakii [26].  
Clinical sources have provided culture positive samples from cerebrospinal 
fluid (CSF), blood, bone marrow, septum, urine, inflamed appendix tissue, 
intestinal and respiratory tracts, eye, ear, wounds, stools and from a 
physicians stethoscope [Adamson 1981, Farmer 1980, [11, 21]. 
 
The existence of a primary reservoir (if any) remains to be determined 
although it has been postulated that the bacteriums natural habitat may be 
associated with plant material, based on some of the physiological 
characteristics of the bacterium, such as its yellow pigment, that can afford a 
measure of protection against harmful ultra-violet light [24]Mullane, 2006).  
 
In epidemiological studies, PIF has been acknowledged as the vehicle of 
transmission for E. sakazakii.  A strong association has been described 
evident between the consumption of contaminated PIF and infection in 
infants[8, 14, 17, 27] France 2004].  Prevalence studies in PIF have been 
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performed[24, 28] FDA, 2003].  Muytjens et al. [28] inspected 141 PIF’s from 
35 countries and isolated E. sakazakii at a frequency of 14.2% representing 
13 countries.  The organism was recovered from powdered samples at levels 
ranging from 0.36 through 0.66 CFU in 100 g samples . More recently the 
WHO reported a prevalence of <1.8% in 6 out of the 12 unrelated studies 
(WHO, 2006).  
 
The first cases of E sakazakii infection linked to the consumption of 
reconstituted PIF were reported in 1988 and involved four infants [REF].  
Since then sporadic cases and outbreaks have been attributed to the 
consumption of contaminated PIF (Table 1).  A review of 48 E. sakazakii 
cases since 1961 revealed that at least 25 were directly linked to the 
consumption of PIF, and PIF was also identified in 85% of these cases as the 
potential source (WHO, 2004).  Similar investigations found E. sakazakii in a 
blender used for the preparation of PIF  (Noriega 1990).  In 1983, six infants 
died following the ingestion of contaminated PIF.  Importantly, in this case, the 
organism was cultured from the PIF previously fed to these infants, along with 
a dish brush used for bottle cleaning and from a spoon used for 
preparation[13]. 
 
An outbreak in Tennessee in 2001 was the first occasion whereby infection 
was attributed and linked to previously unopened cans belonging to the same 
batch of powder[27].  In Belgium in 2002, an infant died of E. sakazakii 
meningitis following consumption of contaminated PIF (FDA).  A follow up 
investigation identified low cell numbers of E. sakazakii and the implicated 
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formula subsequently was withdrawn.  In New Zealand in 2004, a premature 
infant died following E. sakazakii meningitis, the bacterium was isolated from 
four asymptomatic infants in the same neonatal intensive ward and PIF was 
identified as the source of infection.  In December 2004, contaminated PIF 
triggered a worldwide product recall following a possible link to two fatal cases 
of E. sakazakii meningitis in France (Wan, 2004).   
 
More recently------Niall I’ll chat to you about this one! 
 
Resistance to antimicrobials 
When a case of E. sakazakii infection is identified, it is important to treat the 
infection as quickly as possible. Successful chemotherapeutic intervention 
requires that the target orgsniasm is susceptible to the antimicrobial agents 
used.  Similar to other members of Enterobacteriaceae E. sakazakii is 
susceptible to a range of antimicrobials of different classes, including: 
aminoglycosides, anti-folates, chloramphenicol, carbapenems, nitrofurantoin, 
tetracyclines and ticarcillin [1].  Some Enterobacteriaceae can exhibit 
resistance to benzylpenicillin, clindamycin, glycopeptides, lincosamides, 
oxacillin, all macrolide antibiotics, rifampicin, and streptogramins[2].  Mullane 
et al[unpublished] tested XX strains against a panel of 25 antibiotics and 
found that the majority were highly susceptibile.  Enterobacter sakazakii have 
been reported to be capable of inactivating cephalothin, sulfamethoxazole, 
and third generation cephalosporin antibiotics.  Resistance to antibiotics like 
ampicillin has arisen from the production of β-lactamases and also the ability 
of many Enterobacteriaceae to alter membrane permeability through the 
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production of membrane porins, thereby reducing the intracellular 
concentration of the drugs [3].  Multidrug treatments should be taken into 
consideration for treatment of infections, while newer antibiotics such as 
trimethoprim-sulfamethoxazole have been found to be successful [5].  
 
Disinfection, we need a few lines to review the AEM findings in reklation to the 
efficacy of disinfectants in terms of cells in planktonic state, dried onto food 
preparation surfaces and in biofilms. 
 
Virulence and pathogenicity 
The pathogenisis of E. sakazakii meningitis is currently poorly defined.  It is 
thought that infection occurs by translocation of the bacterium through the 
cordus plexus followed by invasion into the previous sterile nutrient rich 
cerebral matter [Iversen, 2003].  No dose-response relationships have been 
published but it is probable that disease progression is host dependant 
requiring a large initial inoculum.  In vitro studies in suckling mice showed that 
of the strains tested, all were lethal at 1x 108 cfu [Pagotto et al.].  The 
infectious dose in humans is unknown.  These authors also examined the 
production of enterotoxin.  Of the 18 strains tested, 4 were found to produce 
enterotoxin in suckling mice. 
 
A few lines reviewing the cell adhesion work-showing adherence to varions 
cell lines, including Caco-2 intestinal cells and a cerebral epithelial cell line. 
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Recent studies indicate that the risk of infection with E. sakazakii can increase 
due to the presence of an endotoxin (bacterial derived lipopolysaccharide) in 
PIF.  This endotoxin is heat stable and survives through the PIF production 
process.  It is postulated that ingestion of the toxin increases the permeability 
of the intestinal epithelium leading to the translocation of E. sakazakii across 
the epithelium barrier [1]. 
 
Another putative virulence factor of E. sakazakii that has been suggested, is 
the production of exopolysaccharide capsular proteins (EPS), which aid in the 
adherence of cells to a variety of surfaces.  Cells have been found attached to 
stainless steel surfaces in hospital environments and on the utensils being 
used for the PIF preparation [2].  Biofilm formation by a number of strains has 
also been reoprted and this is a defence mechanism that promotes resistance 
to disinfectants and sanitizing agents.  Recent studies investigating the 
efficacy of different a range of chemical-based disinfectants used in the 
clinical setting have found that all were effective against planktonic cells.  
When cells were dried onto food preparation surfaces, the efficacy of some 
was reduced and when the cells were contained as opart of a biofilm, none of 
these agents were effective.  These findings suggest that the choice of 
sanatising agent and where it is to be applied, may have serious 
consequences for the dissemination of this organisms in manufacturing, 
health care and home settings.  Chlorine, chlorine dioxide and Tsunami 200 
were all found to reduce E. sakazakii numbers [3].  Quaternary ammonium-
based compounds were the best and these contained the active agent, n-
Alkyl dimethyl (60% C14, 30% C16, 5% C12, 5% C18), benzyl ammonium 
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chlorides and n-Alkyl dimethyl ethybenzyl ammonium chlorides.  
Environments of high alkalinity can lyse the membrane of Gram-negative 
bacteria, which results in leakage of the cytoplasm and death of the cell. 
Quaternary ammonium compound disinfectants could be used on all surfaces 
and preparation equipment for PIF [4]. 
 
Successful adherence to a target cell is likely the first step in the infection 
pathway.  Mange et al., investigated the ability of different E. sakazakii strains 
to colonize two intestinal epithelial cell lines, Hep-2 and Caco-2 and the 
microvascular endothelial cell line HBMEC.  Adherence to these cells was 
maximal at late exponential phase, with a 10-fold increase reported during this 
period of growth [Mange et al.]. 
 
All Enterobacteriaceae possess efflux pumps that can extrude a range of 
xenobiotic compounds from the cell cytoplasm.  In Salmonella, 
Campylobacter and other enteric organisms, bile acids are a natural substrate 
for these membrane bound complexes.  Active efflux is a recognised virulence 
mechanism which contributes to the survival of these pathogens in the host 
gastrointestinal tract.  Further, they also contribute to resistance facilitating the 
bacteriums  survival in the presence of sanitizers and disinfectants [4].  Little 
is known about the involvement of efflux in E. sakazakii. 
 
Laboratory identification of E. sakazakii 
Suitable detection methods are required to reliably isolate and distinguish 
between E. sakazakii and other closely related Enterobacteriaceae that can 
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be found in PIF (REF).  At present there is no internationally validated 
protocol for the specific detection of E. sakazakii.  However, selective 
microbiological culture media has been formulated based on the inclusion of 
either a chromogenic or flurogenic substrate for an enzyme -glucosidase[29-
33] http://www.aeslaboratoire.com/cgi-bin/go_produits.pl, ISO).  Currently an ISO 
method (DTS 22964) which is being evaluated, incorporates one such 
selective agar.  Initially, a pre-enrichment step is carried out, whereby the PIF 
is enriched in buffered peptone water, followed by enrichment in modified 
lauryl sulphate broth (mLST).  A 100 ml volume is then surface plated onto a 
selective agar.  Confirmation is performed by (a) streaking presumptive 
colonies to TSA and examining them for their characteristic “yellow pigment” 
production and (b) biochemical confirmation using the API20E or API32E 
identification galleries(bioMérieux, France.  This approach has been adopted 
and is now being implemented as part of the revised EU microbiological 
criteria (EC 852/2004) for PIF.  However, it should be noted that -
glucosidase negative E. sakazakii strains have been identified[32] and there 
are also other -glucosidase positive Enterobacteriaceae[24] both of which 
could result in errors in diagnosis.  Furthermore, Iversen at al. (2006) recently 
reported that 2% of E. sakazakii strains surveyed failed to produce a yellow 
pigment on TSA[34] while others questioned the reliability of API test 
systems[29, 32]. 
 
As an aid to facilitate the confident identification of E. sakazakii,  several 
molecular-based methods have been published molecular based.  Some of 
these are based on the detection of conserved regions of the E. sakazakii 
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genome [35-37]Hassan 2006, Malorny, 2005].  One such method reported by 
Seo and Brackett, 2005 targeted the macromolecular synthesis (MMS) operon 
and discriminated E. sakazakii from 68 Enterobacter and 55 non-Enterobacter 
strains tested[37]. 
 
Currently the Codex Alimentarius Commission is conducting a risk 
assessment on the microbiological safety and safe preparation of infant 
formula.  This Commission is reviewing the code of hygienic practice for foods 
for infants and children, and a microbiological criteria has been set wjich 
requires the absence of E. sakzakii in 10 g of powder has been introduced by 
the European Commission (EC 2073:2005) (WHO, 2004&2006, 
http://www.fsai.ie/legislation/food/eu_docs/Food_hygiene/Reg2073_2005.pdf L338/11). 
These microbiological criteria provide product specification guidance to PIF 
manufacturers on the acceptability of their product and should form part of 
good hygienic practice regime during manufacturing, handling and distribution 
processes.  
 
Molecular surveillance of E. sakazakii 
Molecular typing methods have long been used to fingerprint clinical 
Enterobacteriaceae isolates associated with nosocomial infections.  
Application of these methods aided our understanding of bacterial 
epidemiology, and are regarded as useful tools to monitor food borne disease.  
The basis of these sub-typing methods relies on the fact that identical isolates 
share highly similar or indistinguishable DNA profiles or fingerprints, to link or 
rule out particular strains in outbreak investigations. 
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Pulsed-field gel electrophoresis (PFGE) has long been recognized as a gold 
standard in molecular sub-typing.  PFGE has been used to investogate the 
relationship among recovered E. sakazakii strains isolated from formula to 
those cultured from infected infants[9] (and smeets 1998).  Other typing 
protocols, including ribotyping and random amplification of polymorphic DNA 
(RADP) have also been used to similar effect[38].  Despite the frequent use of 
PFGE in clinical settings, the food industry has been slower to embrace this 
approach.  Nevertheless, PFGE is now beginning to from an important part of 
the surveillance plan, wherein it can provide a useful backup to HACCP plans 
aimed at limiting transmission of spoilage and pathogenic food borne 
organisms.  Add two lines to update your findings. 
 
Food Safety and Public Health Implications of E. sakazakii  
It is important to understand that PIF is not a microbiologically sterile product.  
Reconstitution and subsequent handling and strorage must recognise the 
importance of maintining temperature control, preventing the rapid grpwth of 
potential contaminating E. sakazakii.  However, commercially available ready-
to-feed liquid infant formula is sterile.  PIF (like dried bovine milk and milk 
products) has been previously documented as a potential source of bacterial 
pathogens such as Bacillus spp., Clostridium spp., Staphylococcus spp. and 
Enterobacteriaceae, notably E. sakazakii, (Townsend et al. 2006; Forsythe, 
2005). 
 
The Codex Alimentarius Commission standards recommend that infants who 
are not breast-fed should be provided with a suitable breast milk substitute 
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that is properly formulated.  PIF has a water activity (aw) of ca. 0.2 and this 
carefully prepared product has been formulated so as to mimic the nutritional 
profile of human milk.  Studies have shown that E. sakazakii can persist for 
very long periods of time in a low aw environment which would normally exist 
in finished PIF product.  Moreover, E. sakazakii was reported to be more 
persistent in PIF than other Enterobacteriaceae including Salmonella and E. 
coli (Caubilla-Barron et al. 2004), highlighting the fact that E. sakazakii is 
more adapted to drying stress than other genera in this family.  While the 
frequency of intrinsic E. sakazakii in powdered milk is of concern, the intrinsic 
concentration of E. sakazakii in PIF typically appears to be low.  It is for this 
reason that the prevention of possible proliferation of this pathogen in situ in 
PIF is critical.  It is now recognised that PIF is epidemiologically linked to 
neonatal infections (Bar-Oz et al. 2001; Nazarowec-White and Farber, 1999; 
Nazarowec-White and Farber, 1997).  Guidelines have been developed by 
FAO/WHO aimed at health care givers and those in the home, alerting them 
to the proper protocols for reconstututing PIF .  These guidelines highlight the 
importance of rapid cooling and feeding of reconstituted PIF where possible.  
It actively discourages prolonged storage and rewarming of reconstituted 
formula.  This approach is supported by scientific evidence which clearly 
shows that improper storage of contaminated reconstitued PIF (ie: 
temperature abuse), supports the rapid growth of E. sakazakii.  Hygenic 
preparation measures therefore remain a significant critical control point in the 
prevention of infection of E. sakazakii from reconstitution PIF.  A summary of 
these general guidelines for the reconstitution of PIF in hospitals and homes 
is given in Table 2. 
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E. sakazakii remains an issue of global concern to the infant formula food 
industry.  Manufacturers are being encouraged to produce a greater range of 
commercially sterile formula products (particularly for high risks groups).  
Efforts are also being made, to reduce the concentration and prevalence of E. 
sakazakii in the manufacturing environment.  This is being done through in-
house environmental monitoring systems and through research programmes.  
The intial control of bacterial populations by the infant food industry and the 
prevention of any potential post process contamination during the production 
of PIF, should have a positive effect on the control of E. sakazakii in the food 
industry. 
 
Conclusions 
Enterobacter sakazakii is a clinically significant pathogen of public health 
concern to neonates and infants.  Its significance has been demonstrated by 
its addition to the list of notifiable diseases in New Zealand (New Zealand 
Ministry of Health, 2005).  While the role of the broader food chain as a 
possible source of contamination of this pathogen remains unknown, 
preventative measures by carers, neonatal units and the infant food industry 
will remain of prominent importance in the prevention of E. sakazakii related 
infections in the near future. 
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